Cambridge Cognition Holdings PLC GBP1 million contract for late phase cancer trial (6873E)
09 Julio 2021 - 1:00AM
UK Regulatory
TIDMCOG
RNS Number : 6873E
Cambridge Cognition Holdings PLC
09 July 2021
Cambridge Cognition Holdings Plc
(" Cambridge Cognition" or the "Company")
Cambridge Cognition wins GBP1 million contract
as the cognitive assessment partner for late phase cancer
trial
Cambridge Cognition Holdings Plc (AIM: COG), which develops and
markets digital solutions to assess brain health, is pleased to
announce that it has won a GBP1 million contract as the cognitive
assessment partner for a late phase cancer trial. This is the
second contract for a top ten pharmaceutical company with a strong
pipeline of oncology products. The revenue from the contract is
expected to be recognised over the next six years.
Oncology is the leading therapeutic area for drug development
and accounted for nearly a third of clinical trials in 2020(1) .
This contract positions the Company in the world's most
consistently active disease space with a client that is committed
to developing oncology therapeutics.
Cancer survival has doubled in the last 40 years in the UK(2) .
With patients now living longer there is a greater focus on
limiting potentially detrimental long-term side effects of both
diagnosis and treatment. One key area is cognitive impairment, for
which deficits have been reported in 90% of patients with brain
tumours and an estimated 30% of patients following chemotherapy(3)
.
Cognitive decline associated with cancer most notably affects
attention, memory, and executive function. The pharmaceutical
company has selected Cambridge Cognition as the cognitive
assessment provider for its pivotal oncology trial as they believe
that CANTAB(TM) cognitive assessments have the sensitivity to
measure these distinct processes. Consequently, CANTAB(TM) will be
used worldwide to determine preservation or improvement in
cognitive function across all 150 trial sites.
Matthew Stork, Chief Executive Officer of Cambridge Cognition,
said:
"Earlier detection and advances in treatment have to led to
considerable improvements in cancer survival rates and, at the same
time, increased attention on the cognitive side-effects. This
pharmaceutical client has a long-standing commitment to improving
outcomes for cancer patients and we are delighted to be supporting
their efforts. We expect that this could become a considerable
growth area for Cambridge Cognition in the future."
References
1. GlobalData. 2020. Oncology dominates clinical trials activity in 2020. https://www.globaldata.com/oncology-dominates-clinical-trials-activity-in-2020-says-globaldata/
2. Cancer Research UK. Cancer survival for all cancers combined. https://www.cancerresearchuk.org/health-professional/cancer-statistics/survival#heading-Zero
3. Assessment and management of cognitive symptoms in patients
with brain tumours, Parsons & Dietrich, American Society of
Clinical Oncology Educational Book 41 (May 19, 2021) e90-e99.x`
For further information, contact:
Cambridge Cognition Holdings Plc Tel: 012 2381 0700
Matthew Stork, Chief Executive Officer press@camcog.com
Michael Holton, Chief Financial Officer
finnCap Ltd (NOMAD and Joint Broker) Tel: 020 7220 0500
Geoff Nash / Simon Hicks (Corporate Finance)
Alice Lane / Charlotte Sutcliffe (Corporate Broking)
Dowgate Capital Limited (Joint Broker) Tel: 020 3903 7715
David Poutney / James Serjeant
IFC Advisory Ltd (Financial PR and IR) Tel: 020 3934 6630
Tim Metcalfe / Graham Herring / Zach Cohen
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a technology company developing digital
health products to better understand, detect and treat conditions
affecting brain health. The Company's software products assess
cognitive health in patients worldwide to improve clinical trial
outcomes, identify and stratify patients early and improve global
efficiency in pharmaceutical and healthcare industries.
For further information visit www.cambridgecognition.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTFZGGNLRMGMZM
(END) Dow Jones Newswires
July 09, 2021 02:00 ET (06:00 GMT)
Cambridge Cognition (LSE:COG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Cambridge Cognition (LSE:COG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024